
    
      This multicenter pivotal clinical trial was comprised of two phases. The first phase, which
      was four weeks in length, was double-blind placebo controlled and was primarily used to
      evaluate the efficacy of buprenorphine/naloxone. The second phase, lasting 48 weeks, was
      primarily conducted to determine the safety of buprenorphine/naloxone.
    
  